Blueprint to Close the Women%E2%80%99s Health Gap 2025

Sex-disaggregated data for ischaemic heart disease and migraine FIGURE 4In contrast, on the upside, the Forum and MHI analysis found that all breast cancer pharmaceutical therapeutics recommended in global CPGs and the WHO’s Model List of Essential Medicines are tracked in global pharmaceutical data. Notably, the comprehensive set of interventions for breast cancer (e.g. radiotherapy, chemotherapy and surgical interventions) are not comprehensively measured across datasets. The breast cancer analysis demonstrates that collecting this type of data is possible and a potentially achievable goal for other conditions. 2.1.3 Publishing sex-disaggregated data could help the understanding of sex-related differences for conditions and their treatments Women are not small men: sex-disaggregated data and analyses allow a better understanding of why and how interventions work differently in men and women, as well as the different effects of interventions attributed to sex and sex-specific physiology. The Forum and MHI analysis found that only around 10% of clinical trials for ischaemic heart disease and migraine published sex-disaggregated data.77 Limited understanding of how women and men may respond differently exacerbates the efficacy gap observed in most health interventions. Proportionate participation by women in clinical trials – relative to their share of the burden – and transparent sharing of sex-disaggregated trial outcomes, side effects and therapeutic dosage could allow scientists to evaluate the efficacy of a treatment.78,79,80 Additionally, none of the clinical trials for ischaemic heart disease and migraine accounted for hormonal fluctuations or menopause in women participants, which impedes the understanding of treatment effectiveness and how therapeutics differ throughout a woman’s life and hormonal stages. Sour ce: The Forum and MHI analysis based on clinical trials completed between 1 January 2022 and 31 December 2022. Data r etrieved June 2024 fr om clinicaltrials.gov Average % of women participating in trials open to all sexes: Average % of women participating in trials open to all sexes: 31% 82%17% 153 26 All sexes Sex-disaggregated results7% 29 2 All sexes Sex-disaggregated resultsMigraine Ischaemic heart disease Out of 320 trials, 153 were open to both sexes and have published data, out of which only 26 (17%) publish sex-disaggregated resultsOut of 52 trials, 29 have published data, out of which only 2 (7%) publish sex-disaggregated results Blueprint to Close the Women’s Health Gap: How to Improve Lives and Economies for All 17